Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life
1 other identifier
observational
106
0 countries
N/A
Brief Summary
S100B, a calcium-binding protein, is found predominantly in the central nervous system (CNS) and is increased in CSF and blood after CNS injury. There are two objectives to this study. 1) To complement our previous study, is urine S100B concentration correlated with gestational age in infants born at \> 28 weeks gestation during the first week of life? 2) Is the urine concentration of S100B affected by intracranial pathology in this gestational age range? Elevation of urine concentration of S100B may be an indicator that the infant will develop serious intracranial pathology and may allow for early initiation of treatment to potentially decrease morbidity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2006
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 3, 2008
CompletedFirst Posted
Study publicly available on registry
September 5, 2008
CompletedJuly 23, 2010
July 1, 2010
8 months
September 3, 2008
July 21, 2010
Conditions
Keywords
Eligibility Criteria
Infants born at \>28 weeks gestation will be eligible for enrollment in this study. Infants with fetal malformations, chromosomal anomalies, clinically significant sepsis (retractable hypotension, neutropenia, and thrombocytopenia), or no urine output for the first 48 hours will be excluded. Infants that meet criteria will be enrolled in this study if the parent(s) sign the consent form. There are no patient safety or adverse event issues as this study is non-invasive and observational only.
You may qualify if:
- Infants born at \>28 weeks gestation will be eligible for enrollment in this study.
You may not qualify if:
- Infants with fetal malformations, chromosomal anomalies, clinically significant sepsis (retractable hypotension, neutropenia, and thrombocytopenia), or no urine output for the first 48 hours will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joanna Beachy, M.D.
University of Utah
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 3, 2008
First Posted
September 5, 2008
Study Start
April 1, 2006
Primary Completion
December 1, 2006
Study Completion
January 1, 2007
Last Updated
July 23, 2010
Record last verified: 2010-07